Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Development of immunotherapeutic strategies targeting IL1RAP in Ewing sarcoma

FY 2023-24

Summary
Immunotherapy empowers the patient's own immune system to fight cancer, training our body's natural defense system to specifically target and destroy diseased cells while leaving healthy ones unharmed. However, to make this work we need a specific marker on the surface of cancer cells that makes them stand out from healthy cells. These markers should be abundant on cancer cells but rare on normal ones.<Our work focusses on Ewing sarcoma (EwS), a particularly aggressive form of bone cancer that mainly affects kids, teenagers, and young adults. When EwS spreads to other parts of the body, survival rates can drop to 15-20%. In our recent research, we found a promising marker for immunotherapy in EwS: a surface protein called IL1RAP. Importantly, IL1RAP is barely found in healthy tissues, making it an ideal target. Our project aims to develop a form of immunotherapy called Chimeric Antigen Receptor (CAR) T cells. T cells are a component of our own immune system that learn to recognize threats within our body and attacks them to protect us. We will reprogram the patient's own T cells to seek out and destroy cancer cells that are marked by IL1RAP. However, getting these CAR-T cells into solid tumors, like EwS, is a challenge. We're working on improving the CAR-T cells' ability to infiltrate and survive within tumors. One avenue we’re pursuing is reprograming another type of immune cells called macrophages to assist CAR-T cells in infiltrating the tumor. We will screen existing drugs that modify macrophage function in combination with the IL1RAP CAR-T to achieve this goal. We will also explore alternative designs for engineering the CAR-T cells to improve their efficacy, such as redesigning the CAR construct to improve recognition and reduce exhaustion.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506107
Name
Huang Yue Zhou (Joe)
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of immunotherapeutic strategies targeting IL1RAP in Ewing sarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Car T Cell; Ewing Sarcoma; Il1rap; Immunotherapy; Metastasis
Abstract
Immunotherapy empowers the patient's own immune system to fight cancer, training our body's natural defense system to specifically target and destroy diseased cells while leaving healthy ones unharmed. However, to make this work we need a specific marker on the surface of cancer cells that makes them stand out from healthy cells. These markers should be abundant on cancer cells but rare on normal ones.<Our work focusses on Ewing sarcoma (EwS), a particularly aggressive form of bone cancer that mainly affects kids, teenagers, and young adults. When EwS spreads to other parts of the body, survival rates can drop to 15-20%. In our recent research, we found a promising marker for immunotherapy in EwS: a surface protein called IL1RAP. Importantly, IL1RAP is barely found in healthy tissues, making it an ideal target. Our project aims to develop a form of immunotherapy called Chimeric Antigen Receptor (CAR) T cells. T cells are a component of our own immune system that learn to recognize threats within our body and attacks them to protect us. We will reprogram the patient's own T cells to seek out and destroy cancer cells that are marked by IL1RAP. However, getting these CAR-T cells into solid tumors, like EwS, is a challenge. We're working on improving the CAR-T cells' ability to infiltrate and survive within tumors. One avenue we&rsquo;re pursuing is reprograming another type of immune cells called macrophages to assist CAR-T cells in infiltrating the tumor. We will screen existing drugs that modify macrophage function in combination with the IL1RAP CAR-T to achieve this goal. We will also explore alternative designs for engineering the CAR-T cells to improve their efficacy, such as redesigning the CAR construct to improve recognition and reduce exhaustion.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huang, Yue Zhou (Joe)
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~